Mer­ck carves out path in first-line ad­vanced cer­vi­cal can­cer with new FDA win for Keytru­da jug­ger­naut

Mer­ck’s PD-(L)1 block­buster Keytru­da has held a steady march in­to ear­li­er lines of ther­a­py, with cer­vi­cal can­cer next up on its check­list. Af­ter flash­ing win­ning da­ta as part of a chemo com­bo last month, Keytru­da now has the FDA’s green light in first-line pa­tients.

The FDA on Wednes­day ap­proved a com­bi­na­tion of Keytru­da plus chemother­a­py with or with­out be­va­cizum­ab to treat first-line per­sis­tent, re­cur­rent or metasta­t­ic cer­vi­cal can­cer, mak­ing it the first PD-(L)1 check­point in­hibitor ap­proved in that set­ting.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER